Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Reperfusion injury is caused due to the damage in the tissue, which occurs due to the lack of blood supply. Examples of reperfusion injury include brain damage after stroke and many others, where reperfusion therapy leads to flow of blood in the tissue which results in inflammation and oxidative damage due to oxidative stress. Reperfusion injury can be treated by therapeutic hypothermia, hydrogen sulphide treatment, cyclosporins, stem cell therapy, and others. Furthermore, delay in reperfusion therapy results in oxidative damage. 

Global Reperfusion Treatment Market – Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic is expected to hamper the global reperfusion treatment market growth during the forecast period. The COVID-19 pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare sector has been impacted majorly due to the COVID-19 pandemic. Many clinical trials have been suspended during the pandemic. In order to restart the clinical trials, the U.S. Food and Drug Administration (FDA) released guidelines during the COVID-19 public health emergency in March 2020. The guidelines were further updated on July 02, 2020. The guidelines include general considerations to assist sponsors and researchers, which ensure the safety of trial participants, and compliance with good clinical practice (GCP) for the duration of the COVID-19 public health emergency. The appendix of the guidelines also provide answers to some general questions, which the U.S. Food and Drug Administration (FDA) received from various sponsors and researchers about conducting clinical trials during the COVID-19 public health emergency. The above guidelines are also applicable for conducting the clinical trials for testing the safety and efficacy of the drugs for the reperfusion injury. Thus, the COVID – 19 pandemic is expected to decrease the growth of the reperfusion treatment market over the forecast period.

The global reperfusion treatment market is estimated to be valued at US$ 1,293.6 million in 2020 and is expected to exhibit a CAGR of 4.5% during the forecast period (2020-2027).

Figure 1: Global Reperfusion Treatment Market Share (%) Analysis, By Treatment Type 2020

Reperfusion Treatment  | Coherent Market Insights

Increasing prevalence of coronary heart dis ease is expected to drive the growth of the global reperfusion treatment market during the forecast period.

The rising incidence of coronary artery disease (CAD) or ischemic heart disease (IHD) is a major factor which is expected to drive the market growth. The CAD or IHD is caused due to the buildup of cholesterol and fatty deposits on the inner walls of the arteries, which may lead to the reduction of blood flow to the heart cells. This condition may lead to ischemia, myocardial infraction or sudden cardiac arrest. Moreover, medicines approved from the regulatory authorities are not available in the market for the treatment of ischemia/reperfusion injury. According to the National Center for Biotechnology Information (NCBI), 2020, in 2017, globally, around 126 million people suffered from ischemic heart disease (1,655 per 100,000), which constituted to 1.72% of the total world population.

Investments and expansion of production facility by market players are expected to boost growth of the global reperfusion treatment market during the forecast period.

Market players are focusing on facility expansions in order to strengthen their product portfolio. For instance, on March 9, 2020, Pharming Group NV received the Food and Drug Administration (U.S. FDA) approval for its new production facility in the Netherlands for the production of the starting material required for manufacturing of RUCONEST. RUCONEST is a C1-esterase inhibitor, which is plasma free and is proven to help treat hereditary angioedema (HAE) attacks. Furthermore, on January 21, 2020, Pharming Group NV received the European Medicines Agency (EMA) approval for the production facility for RUCONEST in Europe.

request-sample

Reperfusion Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 1,293.6 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.5% 2027 Value Projection: US$ 1,758.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment Type: Therapeutic Hypothermia, Cyclosporin, Stem cell Therapy, Hydrogen Sulphide Treatment, Others.
  • By Injury Type: Heart Injury, Kidney Injury, Intestine Injury, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others.
Companies covered:

Corline Biomedical AB, SBI Holdings Inc., Pharming Group NV, Mallinckrodt Pharmaceuticals, MIFCOR, Inc., CFM Pharma Holding B.V., Balmes Transplantation SAS, Revive Therapeutics Ltd., Faraday Pharmaceuticals, Radikal Therapeutics Inc., Amyndas Pharmaceuticals, Perfusion.com, Inc., Angion Biomedica Corp., Young Therapeutics, LLC, Ischemix, Stealth Biotherapeutics Inc., and Bolder Bio Technology Inc.

Growth Drivers:
  • Increasing prevalence of cardiovascular diseases
  • Expansion of production facilities
Restraints & Challenges:
  • Multiple organ failure during the reperfusion treatment

Global Reperfusion Treatment Market – Restraints

There are some side effects associated with the treatment, which are expected to restrain the global reperfusion treatment market during the forecast period. Ischemia reperfusion causes the mediator to infiltrate other tissues, which leads to Multiple Organ Dysfunction Syndrome (MODS). For instance, according to an article published in the International Institute of Anticancer Research in 2019, Multiple Organ Dysfunction Syndrome (MODS) was the leading cause of mortality globally and the incidence of MODS ranged from 25-40%. Furthermore, according to the Critical Care Nephrology Journal 2019, the pediatric multiple organ dysfunction syndrome (MODS) epidemiology ranges from 10% to 50% of the children admitted to the pediatric intensive care unit.

Global Reperfusion Treatment Market – Regional Analysis

On the basis of region, the global reperfusion treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to dominate the global reperfusion treatment market during the forecast period owing to research and development in the region. For instance, in November 2019, Faraday Pharmaceuticals announced positive results from phase II clinical trials of FDY-5301 for ischemia reperfusion injury treatment, following a STEMI heart attack. FDY-5301 is a formulated, patented, elemental reducing agent that contains sodium iodide. It destroys the hydrogen peroxide that is naturally generated as a response to acute ischemia reperfusion injury and also contributes to loss of muscle function and mass.

Europe is an emerging reperfusion treatment market owing to the funding provided for research and development by regulatory authorities. For instance, in February 2019, Balmes Transplantation SAS received around US$ 605,597 million from the European Regional Development Fund (ERDF) for its research program REMEDIRA for developing combinations of repurposed drugs against kidney ischemia-reperfusion injury (IRI).

Figure 2: Global Reperfusion Treatment Market Value (US$ Mn), by Region, 2020

Reperfusion Treatment  | Coherent Market Insights

Global Reperfusion Treatment Market - Competitive Landscape

Some of the key players operating in the global reperfusion treatment market are Corline Biomedical AB, SBI Holdings Inc., Pharming Group NV, Mallinckrodt Pharmaceuticals, MIFCOR, Inc., CFM Pharma Holding B.V., Balmes Transplantation SAS, Revive Therapeutics Ltd., Faraday Pharmaceuticals, Radikal Therapeutics Inc., Amyndas Pharmaceuticals, Perfusion.com, Inc., Angion Biomedica Corp., Young Therapeutics, LLC, Ischemix, Stealth Biotherapeutics Inc., and Bolder Bio Technology Inc.

Reperfusion therapy is used to restore the blood flow in blocked arteries after a heart attack. Reperfusion injury is usually developed due injury to organs during transplantation and others. Patients are treated using anti-platelet therapy, open or endovascular revascularization, coronary angioplasty, and others. Reperfusion injury can occur in organs such as heart, kidney, liver, intestine, lungs, and brain. Currently, clinical trials are being conducted for medicines for the treatment of reperfusion injury.

Market Dynamics

Market players are focusing on various inorganic growth strategies such as mergers and collaborations to strengthen their position in the global market. This is expected to drive the growth of the global reperfusion treatment market during the forecast period. In January 2018, Perfusion.com, Inc. and HEME Perfusion, Inc., providers of outsourced perfusion services, announced their merger. Under this merger agreement, the companies combined their business operations in 2019 and currently operate under the Perfusion.com brand.

Market players are focusing on conducting preclinical trials for a lead product candidate molecule to test the safety and effectiveness of the product in animals. For instance, in 2019, Ischemix conducted preclinical trials for studying the effects of its lead product candidate molecule, CMX-2043, in the treatment of traumatic brain injury. The trials showed positive results by decreasing mitochondrial reactive oxygen species and increasing mitochondrial bioenergetics. Therefore, the lead product reduces the injuries induced by reactive oxygen species in the brain of the animals. Furthermore, the company is planning to carry out phase I trials for the traumatic brain injury in humans.

Key features of the study:

  • This report provides in-depth analysis of the global reperfusion treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global reperfusion treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study are Corline Biomedical AB, SBI Holdings Inc., Pharming Group NV, Mallinckrodt Pharmaceuticals, MIFCOR, Inc., CFM Pharma Holding B.V., Balmes Transplantation SAS, Revive Therapeutics Ltd., Faraday Pharmaceuticals, Radikal Therapeutics Inc., Amyndas Pharmaceuticals, Perfusion.com, Inc., Angion Biomedica Corp., Young Therapeutics, LLC, Ischemix, Stealth Biotherapeutics Inc., and Bolder Bio Technology Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global reperfusion treatment market report caters to various stakeholders in this industry including investors, suppliers, reperfusion therapy manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global reperfusion treatment market.

Detailed Segmentation

  • Global Reperfusion Treatment Market, By Treatment Type,
    • Therapeutic Hypothermia
    • Cyclosporin
    • Stem Cell Therapy
    • Hydrogen Sulphide Treatment
    • Others
  • Global Reperfusion Treatment Market, By Injury Type,
    • Heart Injury
    • Kidney Injury
    • Intestine Injury
    • Others
  • Global Reperfusion Treatment Market, By Distribution Channel,
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others
  • Global Reperfusion Treatment Market, By Region,
    • North America
      • By Country
        • U.S.
        • Canada
      • By Treatment Type
        • Therapeutic Hypothermia
        • Cyclosporin
        • Stem Cell Therapy
        • Hydrogen Sulphide Treatment
        • Others
      • By Injury Type
        • Heart Injury
        • Kidney Injury
        • Intestine Injury
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Treatment Type
        • Therapeutic Hypothermia
        • Cyclosporin
        • Stem Cell Therapy
        • Hydrogen Sulphide Treatment
        • Others
      • By Injury Type
        • Heart Injury
        • Kidney Injury
        • Intestine Injury
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Treatment Type
        • Therapeutic Hypothermia
        • Cyclosporin
        • Stem Cell Therapy
        • Hydrogen Sulphide Treatment
        • Others
      • By Injury Type
        • Heart Injury
        • Kidney Injury
        • Intestine Injury
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Treatment Type
        • Therapeutic Hypothermia
        • Cyclosporin
        • Stem Cell Therapy
        • Hydrogen Sulphide Treatment
        • Others
      • By Injury Type
        • Heart Injury
        • Kidney Injury
        • Intestine Injury
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Treatment Type
        • Therapeutic Hypothermia
        • Cyclosporin
        • Stem Cell Therapy
        • Hydrogen Sulphide Treatment
        • Others
      • By Injury Type
        • Heart Injury
        • Kidney Injury
        • Intestine Injury
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Treatment Type
        • Therapeutic Hypothermia
        • Cyclosporin
        • Stem Cell Therapy
        • Hydrogen Sulphide Treatment
        • Others
      • By Injury Type
        • Heart Injury
        • Kidney Injury
        • Intestine Injury
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
  • Company Profiles
    • Corline Biomedical AB*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • SBI Holdings Inc.
    • Pharming Group NV
    • Mallinckrodt Pharmaceuticals
    • MIFCOR, Inc.
    • CFM Pharma Holding B.V.
    • Balmes Transplantation SAS
    • Revive Therapeutics Ltd.
    • Faraday Pharmaceuticals
    • Radikal Therapeutics Inc.
    • Amyndas Pharmaceuticals
    • com, Inc.
    • Angion Biomedica Corp.
    • Young Therapeutics, LLC
    • Ischemix
    • Stealth Biotherapeutics Inc.
    • Bolder Bio Technology Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment Type
      • Market Snippet, By Injury Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Regulatory Scenario
    • Epidemiology
    • Key Developments
    • Market Trends
    • Merger and Acquisitions
    • New Product Approvals/Launch
    • Technology Evolution
    • PEST Analysis
    • PORTER’s Analysis
  4. Global Reperfusion Treatment Market - Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Impact of COVID-19 on Clinical Trials and Drug Development
    • COVID-19 Impact on Overall Drugs Market
  5. Global Reperfusion Treatment Market, By Treatment Type, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Therapeutic Hypothermia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Cyclosporin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Stem Cell Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Hydrogen Sulphide Treatment
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  6. Global Reperfusion Treatment Market, By Injury Type, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2016 - 2027
      • Segment Trends
    • Heart Injury
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Kidney Injury
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Intestine Injury
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  7. Global Reperfusion Treatment Market, By Distribution Channel, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  8. Global Reperfusion Treatment Market, By Region, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 - 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Injury Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Injury Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • Germany
        • K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Injury Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Injury Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Injury Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Injury Type, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 - 2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Corline Biomedical AB
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • SBI Holdings Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Pharming Group NV
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Mallinckrodt Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • MIFCOR, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • CFM Pharma Holding B.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Balmes Transplantation SAS
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Revive Therapeutics Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Faraday Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Radikal Therapeutics Inc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Amyndas Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • com, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Angion Biomedica Corp.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Young Therapeutics, LLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Ischemix
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Stealth Biotherapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Bolder Bio Technology Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 37 market data tables and 25 figures on "Reperfusion Treatment Market” - Global Forecast to 2027”.

Frequently Asked Questions

The global reperfusion treatment market is expected to exhibit a CAGR of 4.5% during the forecast period (2020-2027).
The value of the global reperfusion treatment market is estimated to be US$ 1,293.6 million in 2020.
Corline Biomedical AB, SBI Holdings Inc., Pharming Group NV, Mallinckrodt Pharmaceuticals, MIFCOR, Inc., CFM Pharma Holding B.V., Balmes Transplantation SAS, Revive Therapeutics Ltd., Faraday Pharmaceuticals, Radikal Therapeutics Inc., Amyndas Pharmaceuticals, Perfusion.com, Inc., Angion Biomedica Corp., Young Therapeutics, LLC, Ischemix, Stealth Biotherapeutics Inc., and Bolder Bio Technology Inc. are some of the prominent players operating in the global reperfusion treatment market.
The global reperfusion treatment market is expected to be valued at US$ 1,758.6 million in 2027.
North America and Europe are the prominent regions in the global reperfusion treatment market.
Increasing prevalence of cardiovascular diseases, research and development, and expansion of production facilities are some of the key factors driving the global reperfusion treatment market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner